Literature DB >> 17097763

Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.

D Economidou1, A Fedeli, R Martin Fardon, F Weiss, M Massi, R Ciccocioppo.   

Abstract

Activation of the NOP receptor by the endogenous ligand nociceptin/orphanin FQ (N/OFQ) reduces alcohol consumption in genetically selected alcohol-preferring Marchigian Sardinian (msP) rats. The present study evaluated the effect of three newly synthesized peptidergic and one brain-penetrating heterocyclic NOP receptor agonists on alcohol drinking in the two bottle choice paradigm. MsP rats were intracerebroventricularly (ICV) injected with the NOP receptor agonists OS-462 (0.5 and 1.0 microg), UFP-102 (0.25 and 1.0 microg) or UFP-112 (0.01 and 0.05 microg), or with Ro 64-6198 (0.3 and 1.0 mg/kg) given intraperitoneally (i.p.) and tested for 10% alcohol consumption. Results showed decreased alcohol consumption after treatment with all three peptidergic NOP receptor agonists (OS-462, UFP-102 and UFP-112). OS-462 (at the 1.0 microg dose) and UFP-102 (at the 0.25 microg dose) induced a significant increase in food intake as well. Surprisingly, Ro 64-6198 was ineffective at the 0.3 mg/kg dose, whereas it increased ethanol and food consumption at the 1.0 mg/kg dose. Pre-treatment with the selective mu-receptor antagonist naloxone (0.5 mg/kg, i.p.) reduced these effects of 1.0 mg/kg of Ro 64-6198. These findings confirm that activation of brain NOP receptors reduces alcohol drinking in msP rats and demonstrate that OS-462, UFP-102 and UFP-112 act as potent NOP receptor agonists. On the other hand, Ro 64-6198 increased alcohol drinking, an effect probably induced by a residual agonist activity of this compound at mu-opioid receptors. Overall, the results indicate that OS-462, UFP-102 and UFP-112 may represent valuable pharmacological tools to investigate the functional role of the brain N/OFQ system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097763      PMCID: PMC1847604          DOI: 10.1016/j.peptides.2006.09.007

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  47 in total

1.  Opioids excite dopamine neurons by hyperpolarization of local interneurons.

Authors:  S W Johnson; R A North
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

2.  Immunohistochemical localization of ORL-1 in the central nervous system of the rat.

Authors:  B Anton; J Fein; T To; X Li; L Silberstein; C J Evans
Journal:  J Comp Neurol       Date:  1996-04-29       Impact factor: 3.215

3.  Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ.

Authors:  J S Mogil; J E Grisel; G Zhangs; J K Belknap; D K Grandy
Journal:  Neurosci Lett       Date:  1996-08-23       Impact factor: 3.046

4.  Orphanin FQ is a functional anti-opioid peptide.

Authors:  J S Mogil; J E Grisel; R K Reinscheid; O Civelli; J K Belknap; D K Grandy
Journal:  Neuroscience       Date:  1996-11       Impact factor: 3.590

5.  A small dose of morphine leads rats to drink more alcohol and achieve higher blood alcohol concentrations.

Authors:  C L Hubbell; R F Mankes; L D Reid
Journal:  Alcohol Clin Exp Res       Date:  1993-10       Impact factor: 3.455

6.  Ventral mesencephalic delta opioid receptors are involved in modulation of basal mesolimbic dopamine neurotransmission: an anatomical localization study.

Authors:  D P Devine; P Leone; W A Carlezon; R A Wise
Journal:  Brain Res       Date:  1993-09-17       Impact factor: 3.252

7.  Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations.

Authors:  C L Hubbell; S A Czirr; G A Hunter; C M Beaman; N C LeCann; L D Reid
Journal:  Alcohol       Date:  1986 Jan-Feb       Impact factor: 2.405

8.  Mesolimbic dopamine neurotransmission is increased by administration of mu-opioid receptor antagonists.

Authors:  D P Devine; P Leone; R A Wise
Journal:  Eur J Pharmacol       Date:  1993-10-12       Impact factor: 4.432

9.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  22 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

4.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

5.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

Review 6.  The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Authors:  Nurulain T Zaveri
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

Authors:  Linda M Rorick-Kehn; Roberto Ciccocioppo; Conrad J Wong; Jeffrey M Witkin; Maria A Martinez-Grau; Serena Stopponi; Benjamin L Adams; Jason S Katner; Kenneth W Perry; Miguel A Toledo; Nuria Diaz; Celia Lafuente; Alma Jiménez; Ana Benito; Concepción Pedregal; Friedbert Weiss; Michael A Statnick
Journal:  Alcohol Clin Exp Res       Date:  2016-04-16       Impact factor: 3.455

8.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

9.  Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.

Authors:  Roberto Ciccocioppo; Serena Stopponi; Daina Economidou; Makoto Kuriyama; Hiroshi Kinoshita; Markus Heilig; Marisa Roberto; Friedbert Weiss; Koji Teshima
Journal:  Neuropsychopharmacology       Date:  2014-06-27       Impact factor: 7.853

10.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.